Pulmoprost
IND- Indications
- Pulmonary Arterial Hypertension
Company intelligence / Profile preview
Infusyn Therapeutics is developing precision dosing solutions using its Prometra II implantable infusion pump. The system is already approved and marketed for chronic pain and spasticity, while the company is advancing a proprietary drug/device program targeting pulmonary arterial hypertension toward an IND filing. No clinical results have been published yet for the PAH program, but commercial use exists in other indications.[1][2][3][4]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Infusyn Therapeutics.